Skip to main content
. 2023 Aug 15;15(8):5258–5266.

Table 5.

Univariate analysis of factors affecting the treatment efficacy

Overall response Group (n=81) Ineffective Group (n=17) χ2/t P
Gender 0.760 0.383
    Male 48 (59.26) 12 (70.59)
    Female 33 (40.74) 5 (29.41)
Age of onset (years) 4.2±1.3 4.3±1.2 0.771 0.292
Average course of disease (days) 5.8±3.4 8.2±2.9 2.708 0.008
Admission body temperature (°C) 38.4±0.6 38.8±0.6 2.499 0.014
Clinical manifestations
    Fever 72 (88.89) 14 (82.35) 0.559 0.455
    Isthmitis 53 (65.43) 16 (94.12) 5.549 0.019
    Cervical lymph node enlargement 65 (80.25) 13 (76.47) 0.123 0.725
Place of residence 0.363 0.547
    Rural area 25 (30.86) 4 (23.53)
    Urban area 56 (69.14) 13 (76.47)
Admission to school or not 2.106 1.451
    Yes 29 (35.80) 3 (17.65)
    No 52 (64.20) 14 (82.35)
Admission IgA 4.47±1.32 5.28±0.74 2.444 0.016
Admission IgG 12.88±3.11 14.75±2.19 2.355 0.021
Admission IgM 1.51±0.32 1.73±0.30 2.603 0.011
Admission white blood cell count 16.20±3.39 18.47±2.09 2.651 0.009
Admission lymphocyte proportion 47.54±6.22 52.04±4.08 2.851 0.005
Treatment mode 5.041 0.025
    Ribavirin 33 (40.74) 12 (70.59)
    Acyclovir 48 (59.26) 5 (29.41)

Notes: IgG: immunoglobulin G, IgA: immunoglobulin A, IgM: immunoglobulin M.